Telmisartan Suppresses Cardiac Hypertrophy by Inhibiting Cardiomyocyte Apoptosis Via the NFAT/ANP/BNP Signaling Pathway

Overview

Journal Mol Med Rep

Specialty Molecular Biology

Date 2017 Apr 28

PMID 28447738

Citations 19

Authors

Xiurong Li

Yuhuai Lan

Yan Wang

Minghao Nie

Yanhong Lu

Eryang Zhao

Affiliations

Soon will be listed here.

Abstract

Telmisartan, a type of angiotensin II (Ang II) receptor inhibitor, is a common agent used to treat hypertension in the clinic. Hypertension increases cardiac afterload and promotes cardiac hypertrophy. However, the ventricular Ang II receptor may be activated in the absence of hypertension. Therefore, telmisartan may reduce cardiac hypertrophy by indirectly ameliorating hypertensive symptoms and directly inhibiting the cardiac Ang II receptor. Nuclear factor of activated T‑cells (NFAT) contributes to cardiac hypertrophy via nuclear translocation, which induces a cascade of atrial natriuretic peptide (ANP) and brain/B‑type natriuretic peptide (BNP) expression and cardiomyocyte apoptosis. However, NFAT-mediated inhibition of cardiac hypertrophy by telmisartan remains poorly understood. The present study demonstrated that telmisartan suppressed cardiomyocyte hypertrophy in a mouse model of cardiac afterload and in cultured cardiomyocytes by inhibiting NFAT nuclear translocation, as well as by inhibiting ANP and BNP expression and cardiomyocyte apoptosis, in a dose‑dependent manner. The present study provides a novel insight into the potential underlying mechanisms of telmisartan-induced inhibition of cardiomyocyte hypertrophy, which involves inhibition of NFAT activation, nuclear translocation and the ANP/BNP cascade.

Citing Articles

Prominent Naturally Derived Oxidative-Stress-Targeting Drugs and Their Applications in Cancer Treatment.

Lee E, Yang D, Hong J Antioxidants (Basel). 2025; 14(1).

PMID: 39857383 PMC: 11760868. DOI: 10.3390/antiox14010049.

TongGuanWan Alleviates Doxorubicin- and Isoproterenol-Induced Cardiac Hypertrophy and Fibrosis by Modulating Apoptotic and Fibrotic Pathways.

Yoon J, Tai A, Kim H, Han B, Shin S, Lee H Int J Mol Sci. 2024; 25(19).

PMID: 39408900 PMC: 11476530. DOI: 10.3390/ijms251910573.

Sibjotang Protects against Cardiac Hypertrophy In Vitro and In Vivo.

Son C, Hong M, Kim H, Han B, Seo C, Lee H Life (Basel). 2023; 13(12).

PMID: 38137908 PMC: 10744393. DOI: 10.3390/life13122307.

The Microenvironment of the Pathogenesis of Cardiac Hypertrophy.

Bazgir F, Nau J, Nakhaei-Rad S, Amin E, Wolf M, Saucerman J Cells. 2023; 12(13).

PMID: 37443814 PMC: 10341218. DOI: 10.3390/cells12131780.

Virtual drug screen reveals context-dependent inhibition of cardiomyocyte hypertrophy.

Eggertsen T, Saucerman J Br J Pharmacol. 2023; 180(21):2721-2735.

PMID: 37302817 PMC: 10592153. DOI: 10.1111/bph.16163.

References

Saha L . Comparison of the efficacy and tolerability of telmisartan and enalapril in patients of mild to moderate essential hypertension. Indian J Pharmacol. 2011; 43(3):360. PMC: 3113399. DOI: 10.4103/0253-7613.81489. View

Maejima Y, Okada H, Haraguchi G, Onai Y, Kosuge H, Suzuki J . Telmisartan, a unique ARB, improves left ventricular remodeling of infarcted heart by activating PPAR gamma. Lab Invest. 2011; 91(6):932-44. DOI: 10.1038/labinvest.2011.45. View

Amerena J, Pappas S, Ouellet J, Williams L, OShaughnessy D . ABPM comparison of the anti-hypertensive profiles of telmisartan and enalapril in patients with mild-to-moderate essential hypertension. J Int Med Res. 2003; 30(6):543-52. DOI: 10.1177/147323000203000601. View

Suenobu N, Shichiri M, IWASHINA M, Marumo F, Hirata Y . Natriuretic peptides and nitric oxide induce endothelial apoptosis via a cGMP-dependent mechanism. Arterioscler Thromb Vasc Biol. 1999; 19(1):140-6. DOI: 10.1161/01.atv.19.1.140. View

Frohlich E, Apstein C, CHOBANIAN A, Devereux R, DUSTAN H, Dzau V . The heart in hypertension. N Engl J Med. 1992; 327(14):998-1008. DOI: 10.1056/NEJM199210013271406. View

Porter A, Janicke R . Emerging roles of caspase-3 in apoptosis. Cell Death Differ. 1999; 6(2):99-104. DOI: 10.1038/sj.cdd.4400476. View

Bohm M, Lippoldt A, Wienen W, Ganten D, Bader M . Reduction of cardiac hypertrophy in TGR(mREN2)27 by angiotensin II receptor blockade. Mol Cell Biochem. 1996; 163-164:217-21. DOI: 10.1007/BF00408661. View

Yamagishi S, Takeuchi M . Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property. Med Hypotheses. 2004; 64(3):476-8. DOI: 10.1016/j.mehy.2004.09.015. View

Mattioli A, Zennaro M, Bonatti S, Bonetti L, Mattioli G . Regression of left ventricular hypertrophy and improvement of diastolic function in hypertensive patients treated with telmisartan. Int J Cardiol. 2004; 97(3):383-8. DOI: 10.1016/j.ijcard.2003.10.018. View

10.

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

11.

Robbs B, Lucena P, Viola J . The transcription factor NFAT1 induces apoptosis through cooperation with Ras/Raf/MEK/ERK pathway and upregulation of TNF-α expression. Biochim Biophys Acta. 2013; 1833(8):2016-28. DOI: 10.1016/j.bbamcr.2013.04.003. View

12.

Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I . Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008; 372(9644):1174-83. DOI: 10.1016/S0140-6736(08)61242-8. View

13.

Muller P, Kazakov A, Semenov A, Jagoda P, Friedrich E, Bohm M . Ramipril and telmisartan exhibit differential effects in cardiac pressure overload-induced hypertrophy without an additional benefit of the combination of both drugs. J Cardiovasc Pharmacol Ther. 2012; 18(1):87-93. DOI: 10.1177/1074248411434773. View

14.

Zou Y, Akazawa H, Qin Y, Sano M, Takano H, Minamino T . Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nat Cell Biol. 2004; 6(6):499-506. DOI: 10.1038/ncb1137. View

15.

Honjo S, Nichi Y, Wada Y, Hamamoto Y, Koshiyama H . Possible beneficial effect of telmisartan on glycemic control in diabetic subjects. Diabetes Care. 2005; 28(2):498. DOI: 10.2337/diacare.28.2.498. View

16.

Bernardo B, Weeks K, Pretorius L, McMullen J . Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies. Pharmacol Ther. 2010; 128(1):191-227. DOI: 10.1016/j.pharmthera.2010.04.005. View

17.

Irani R, Zhang Y, Blackwell S, Zhou C, Ramin S, Kellems R . The detrimental role of angiotensin receptor agonistic autoantibodies in intrauterine growth restriction seen in preeclampsia. J Exp Med. 2009; 206(12):2809-22. PMC: 2806612. DOI: 10.1084/jem.20090872. View

18.

Tokudome T, Horio T, Kishimoto I, Soeki T, Mori K, Kawano Y . Calcineurin-nuclear factor of activated T cells pathway-dependent cardiac remodeling in mice deficient in guanylyl cyclase A, a receptor for atrial and brain natriuretic peptides. Circulation. 2005; 111(23):3095-104. DOI: 10.1161/CIRCULATIONAHA.104.510594. View

19.

Diep Q, El Mabrouk M, Yue P, Schiffrin E . Effect of AT(1) receptor blockade on cardiac apoptosis in angiotensin II-induced hypertension. Am J Physiol Heart Circ Physiol. 2002; 282(5):H1635-41. DOI: 10.1152/ajpheart.00984.2001. View

20.

Derosa G, Ragonesi P, Mugellini A, Ciccarelli L, Fogari R . Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Hypertens Res. 2004; 27(7):457-64. DOI: 10.1291/hypres.27.457. View